Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
1.
J Geriatr Oncol ; 15(5): 101796, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38761773

RESUMEN

INTRODUCTION: Supportive care needs may vary according to age. The purpose of this research is to describe and compare supportive care needs between older adults with metastatic cancer (age ≥ 65 years) and their younger counterparts. MATERIALS AND METHODS: We conducted a retrospective secondary analysis of a cohort of patients with newly diagnosed metastatic solid tumors. Supportive care needs were assessed at baseline and at a three-month follow-up. Patients were divided into two groups (aged ≥65/<65 years). Differences in clinical characteristics and supportive care needs were compared utilizing descriptive statistics. Multivariate logistic regression models were employed to identify patient characteristics associated with specific supportive care needs. RESULTS: Between 2018 and 2022, 375 patients were enrolled. Median age was 66 years (interquartile range 19-94). At baseline, older adults had a higher number of supportive care needs (4.8 vs. 4.2, p = 0.01) and were at higher risk of malnutrition (75 vs. 65%, p = 0.05). Increasing age (odds ratio [OR] 1.02 (95% confidence interval [CI] 1.0-1.04, p = 0.03) and an estimated life expectancy <6 months (OR 3.0, 95%CI 1.5-6.1; p < 0.01) were associated with higher odds of malnutrition, while a higher educational level was associated with decreased odds (OR 0.68, 95%CI 0.5-0.8; p < 0.01). At three-month follow-up, older adults still had a higher number of supportive care needs (3.8 vs.2.6, p < 0.01) and were more likely to have fatigue (62 vs. 47%, p = 0.02). An estimated life expectancy of <6 months was associated with increased odds of fatigue (OR 3.0, 95%CI 1.5-6.3; p < 0.01). DISCUSSION: Older adults reported significantly more supportive care needs, particularly risk of malnutrition and fatigue. This information can help in the creation of supportive care services tailored to the needs of older individuals.


Asunto(s)
Neoplasias , Humanos , Anciano , Masculino , Femenino , Estudios Retrospectivos , Anciano de 80 o más Años , Neoplasias/terapia , México/epidemiología , Persona de Mediana Edad , Factores de Edad , Adulto , Metástasis de la Neoplasia , Desnutrición/epidemiología , Adulto Joven , Cuidados Paliativos , Evaluación de Necesidades , Necesidades y Demandas de Servicios de Salud , Modelos Logísticos , Fatiga/epidemiología
2.
Rev. mex. anestesiol ; 45(4): 244-252, oct.-dic. 2022. tab
Artículo en Español | LILACS-Express | LILACS | ID: biblio-1431917

RESUMEN

Resumen: Introducción: Los cuidados paliativos en México son contemplados como una necesidad en todos los niveles de atención. La nutrición e hidratación en estos enfermos hacia sus últimos días de vida es controversial. Objetivo: Identificar las recomendaciones basadas en la evidencia sobre la nutrición e hidratación en los últimos días de vida. Material y métodos: Se realizó una búsqueda documental sobre la nutrición e hidratación hacia el final de la vida tomando como marco temporal las últimas horas y/o los últimos días de vida del enfermo en el contexto hospitalario. Resultados: Con los criterios de búsqueda seleccionados se identificaron 83 documentos. No se encontraron metaanálisis. Existen dos revisiones sistematizadas de la literatura, un ensayo clínico, cuatro guías de práctica clínica, cuatro reportes de caso y 17 revisiones. Se desglosan los resultados relevantes de lo seleccionado. Conclusiones: Se identifica que existen controversias de fondo sobre la alimentación al final de la vida. Sobre la hidratación existe cierto consenso. Es indispensable contar con un nutriólogo dentro de los servicios de cuidados paliativos de la Nación.


Abstract: Introduction: Palliative care in Mexico is considered a necessity at all levels of care. Nutrition and hydration in these patients towards the last days of life is controversial. Objective: To identify evidence-based recommendations on nutrition and hydration in the last days of life. Material and methods: A documentary search on nutrition and hydration towards the end of life was carried out taking as a time frame the last hours and/or the last days of life of the patient in the hospital context. Results: With the selected search criteria, 83 documents were identified. No meta-analyses were found. There are two systematized literature reviews, one clinical trial, four clinical practice guidelines, four case reports and 17 reviews. The relevant results of the selected documents are broken down. Conclusions: It is identified that there are fundamental controversies about feeding at the end of life. On hydration there is some consensus. It is essential to have a nutritionist within the palliative care services of the Nation.

3.
World J Gastroenterol ; 27(22): 3050-3063, 2021 Jun 14.
Artículo en Inglés | MEDLINE | ID: mdl-34168407

RESUMEN

Minimal hepatic encephalopathy (MHE) corresponds to the earliest stage of hepatic encephalopathy (HE). MHE does not present clinically detectable neurological-psychiatric abnormalities but is characterized by imperceptible neurocognitive alterations detected during routine clinical examination via neuropsychological or psychometrical tests. MHE may affect daily activities and reduce job performance and quality of life. MHE can increase the risk of accidents and may develop into overt encephalopathy, worsening the prognosis of patients with liver cirrhosis. Despite a lack of consensus on the therapeutic indication, interest in finding novel strategies for prevention or reversion has led to numerous clinical trials; their results are the main objective of this review. Many studies address the treatment of MHE, which is mainly based on the strategies and previous management of overt HE. Current alternatives for the management of MHE include measures to maintain nutritional status while avoiding sarcopenia, and manipulation of intestinal microbiota with non-absorbable disaccharides such as lactulose, antibiotics such as rifaximin, and administration of different probiotics. This review analyzes the results of clinical studies that evaluated the effects of different treatments for MHE.


Asunto(s)
Encefalopatía Hepática , Encefalopatía Hepática/diagnóstico , Encefalopatía Hepática/etiología , Encefalopatía Hepática/terapia , Humanos , Lactulosa/uso terapéutico , Cirrosis Hepática/complicaciones , Cirrosis Hepática/diagnóstico , Cirrosis Hepática/terapia , Calidad de Vida , Rifaximina/uso terapéutico
4.
Ann Hepatol ; 18(6): 879-882, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31506216

RESUMEN

INTRODUCTION AND OBJECTIVES: Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune disease that disrupts the cholesterol metabolism. Our aim was to investigate the frequency of dyslipidemias and to evaluate the risk of cardiovascular events in a historic cohort of patients with PBC. PATIENTS: All patients attended from 2000 to 2009 with histological diagnosis of PBC were included and were compared with healthy controls. The 10-year cardiovascular risk was estimated by the Framingham risk score. RESULTS: Fifty four patients with PBC were included and compared to 106 controls. Differences in total cholesterol (263.8±123.9mg/dl vs. 199.6±40, p=0.0001), LDL-cholesterol (179.3±114.8 vs. 126.8±34.7, p=0.0001), HDL-cholesterol (62.4±36.2mg/dl vs. 47.3±12.3, p=0.0001) and triglycerides (149.1±59.1mg/dl vs. 126.4±55.4, p=0.001) were found. Hypercholesterolemia (>240mg/dl) was found in 52.4% of the patients with PBC vs. 11% in the control group, high LDL-cholesterol (160-189mg/dl) in 45.2% of the patients with PBC vs. 10% in controls and hyperalphalipoproteinemia (HDL-cholesterol >60mg/dl) in 45.2% of the patients with PBC vs. 16% in controls. The 10-year cardiovascular risk was 5.3%±5.9 in the patients with PBC and 4.1%±5.7 in the control group (p=0.723, IC 95%=0.637-1.104). Only one cardiovascular event (stroke) in a patient with PBC was registered in a mean follow up time of 57.9±36.5 months. CONCLUSIONS: Marked derangements in serum lipids and a high frequency of dyslipidemias are found in patients with PBC, however, these do not increase the risk of cardiovascular events.


Asunto(s)
HDL-Colesterol/sangre , LDL-Colesterol/sangre , Dislipidemias/sangre , Cirrosis Hepática Biliar/sangre , Triglicéridos/sangre , Adulto , Factores de Edad , Anciano , Presión Arterial , Enfermedades Cardiovasculares/epidemiología , Estudios de Casos y Controles , Diabetes Mellitus/epidemiología , Dislipidemias/epidemiología , Femenino , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/epidemiología , Hiperlipoproteinemias/sangre , Hiperlipoproteinemias/epidemiología , Cirrosis Hepática Biliar/epidemiología , Masculino , Persona de Mediana Edad , Medición de Riesgo , Factores Sexuales , Fumar/epidemiología , Accidente Cerebrovascular/epidemiología
5.
Rev Invest Clin ; 70(3): 121-125, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29943772

RESUMEN

Malnutrition and muscle wasting are common features of cancer cachexia that may interfere with the patient's response to cancer treatment, survival, and quality of life. An accurate nutritional screening at the time of diagnosis and throughout the patient's treatment fosters better control of the disease. Several screening tools have proven to be useful for this purpose. Nevertheless, nutritional evaluation is not a routine practice in this clinical setting and procedures must be standardized. Nutritional risk screening (NRS), malnutrition screening tool (MST), and patient-generated subjective global assessment (PG-SGA) are the most common screening tools, and each one possesses some benefits when screening patients for malnutrition; however, weight loss over a specific time period, dietary intake and anorexia must also be considered. The body mass index-adjusted weight loss grading system predicts survival. We recommend the application of MST or NRS, followed by PG-SGA, food intake determination, measurement of body weight, and its changes as well as body composition, biochemical nutritional markers, muscle function, and physical performance.


Asunto(s)
Desnutrición/diagnóstico , Neoplasias/terapia , Evaluación Nutricional , Índice de Masa Corporal , Peso Corporal , Caquexia/etiología , Caquexia/terapia , Humanos , Desnutrición/etiología , Tamizaje Masivo/métodos , Neoplasias/complicaciones , Estado Nutricional , Calidad de Vida , Riesgo
6.
Minerva Gastroenterol Dietol ; 63(3): 257-263, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28185444

RESUMEN

BACKGROUND: Cis-palmitoleic acid (Omega-7 fatty acid) is a monounsaturated fatty acid (MUFA) associated with anti-inflammatory process through specific protein interactions such as HNF4γ and HNF4α, these two genes are related to the immune response in ulcerative colitis (UC) they may act as a mediator of anti-inflammatory action. The aim of this study was to evaluate the effect of Cis-palmitoleic acid supplementation on inflammatory activity and the expression of genes HNF4γ, HNF4α and IL6 in the colonic mucosa of patients with active UC. METHODS: A double-blind, randomized, placebo-controlled pilot study was conducted in 20 patients with UC. A dose of 720 mg/day of Cis-palmitoleic acid was orally administered during 8 weeks and Mayo Clinic score was used for the assessment of clinical activity in UC before and after treatment with Cis-palmitoleic acid and placebo. RESULTS: A total of 20 patients with UC were randomized to receive Cis-palmitoleic acid or placebo. Significant changes in the biochemical markers of inflammation were found in UC patients before and after treatment with Cis-palmitoleic acid vs. placebo such as total protein (P=0.02), hs-CRP (P=0.04) and ESR (P<0.05). The gene expression of HNF4γ and HNF4α were found to be increased in the Cis-palmitoleic acid group compared to placebo group (P=0.05 and P=0.07 respectively) as well as significant reduction upon IL6 expression in the Cis-palmitoleic acid group (P=0.005). CONCLUSIONS: Cis-palmitoleic acid as co-adjuvant therapy for 8 weeks seems to decrease the inflammatory activity through the increased expression of HNF4α and HNF4γ in patients with UC.


Asunto(s)
Colitis Ulcerosa/tratamiento farmacológico , Ácidos Grasos Monoinsaturados/uso terapéutico , Factor Nuclear 4 del Hepatocito/metabolismo , Interleucina-6/metabolismo , Adulto , Biomarcadores/metabolismo , Método Doble Ciego , Femenino , Factor Nuclear 4 del Hepatocito/genética , Humanos , Inflamación/tratamiento farmacológico , Interleucina-6/genética , Masculino , Proyectos Piloto , ARN Mensajero/metabolismo
7.
Gac Med Mex ; 152 Suppl 1: 5, 2016 Sep.
Artículo en Español | MEDLINE | ID: mdl-27603880

RESUMEN

El presente suplemento tiene como propósito mostrar el contexto y una guía clínica sobre el consumo y papel de la leche de vaca en la alimentación. El contenido considera el papel de la leche y productos lácteos en diferentes estados fisiológicos, etapas de vida y patologías. Se basa en la mejor evidencia científica disponible y está dirigido a profesionales de la salud de diferentes especialidades.


Asunto(s)
Productos Lácteos , Leche , Valor Nutritivo , Animales
8.
Gac Med Mex ; 152 Suppl 1: 35-9, 2016 Sep.
Artículo en Español | MEDLINE | ID: mdl-27603885

RESUMEN

Adulthood starts after youth and is characterized by the completion of growth and the achievement of organic and psychological maturity. Obesity and other preventable diseases related to lifestyle are common at this age. A complete, balanced and sufficient diet, together with exercise are important in order to prevent and treat these diseases. Several studies have brought about the mechanisms by which the incorporation of milk and dairy products to diet is beneficial in order to prevent and treat these diseases. Milk also contributes to the improvement of dental, bone and intestinal health, theoretically helps in body weight control, has a definite role on the muscular and bone mass maintenance and is an option for hydration during exercise, this being as important as diet for overweight, obesity, diabetes, dislipidemias and hypertension control.


Asunto(s)
Dieta , Ejercicio Físico , Estilo de Vida , Leche , Sobrepeso/prevención & control , Adulto , Animales , Índice de Masa Corporal , Huesos/fisiología , Fenómenos Fisiológicos Cardiovasculares , Dentición Permanente , Ejercicio Físico/fisiología , Humanos , Fenómenos Fisiológicos Musculoesqueléticos , Obesidad/etiología , Obesidad/prevención & control , Sobrepeso/etiología
9.
Ann Hepatol ; 10 Suppl 2: S45-9, 2011 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22228881

RESUMEN

The prevalence of under nutrition in cirrhotic patients is 61% and it usually progresses as the disease becomes more advanced. The deterioration in the nutritional status and its associated metabolic derangements has raised doubts about the benefits of severe and prolonged protein restriction as a treatment for hepatic encephalopathy. However, the practice of dietary protein restriction for patients with liver cirrhosis is deeply embedded among medical practitioners and dietitians. To date, no solid conclusions may be drawn about the benefit of protein restriction. However, the negative effects of protein restriction are clear, that is, increased protein catabolism, the release of amino acids from the muscle, and possible worsening of hepatic encephalopathy. In conclusion, chronic protein restriction causes progressive and harmful protein depletion and must be avoided.


Asunto(s)
Encefalopatía Hepática/dietoterapia , Encefalopatía Hepática/fisiopatología , Apoyo Nutricional , Enfermedad Crónica , Proteínas en la Dieta/efectos adversos , Proteínas en la Dieta/uso terapéutico , Encefalopatía Hepática/etiología , Humanos , Cirrosis Hepática/complicaciones , Cirrosis Hepática/dietoterapia , Estado Nutricional , Índice de Severidad de la Enfermedad
10.
Rev Gastroenterol Mex ; 72(2): 122-5, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17966372

RESUMEN

Cystic tumours of the spleen are generally rare, and a parasitic origin is relatively unlikely. The present case report shows, however that when a splenic cyst is found, the differential diagnosis must always consider the possibility of echinococcosis. We report the case of a patient suffering from a cystic lesion of the spleen where surgery and histopathology yielded the diagnosis of splenic echinococcosis. Abdominal pain in the left upper quadrant and splenomegaly detected by simple abdominal radiology are the most commonly found indicators for this disease. The treatment should be surgical, attempting to preserve as much splenic tissue as possible, although conservative treatment is frequently unfeasable due to massive involvement of the spleen. Although rare, splenic hydatidosis should be included in the differential diagnosis when a cystic splenic lesion is identified with sonography or CT scan.


Asunto(s)
Equinococosis/diagnóstico , Enfermedades del Bazo/diagnóstico , Dolor Abdominal/etiología , Adulto , Quistes/diagnóstico , Diagnóstico Diferencial , Equinococosis/diagnóstico por imagen , Equinococosis/patología , Equinococosis/cirugía , Femenino , Humanos , Bazo/patología , Enfermedades del Bazo/diagnóstico por imagen , Enfermedades del Bazo/patología , Enfermedades del Bazo/cirugía , Esplenomegalia/etiología , Tomografía Computarizada por Rayos X , Ultrasonografía
11.
Rev Gastroenterol Mex ; 70(4): 465-74, 2005.
Artículo en Español | MEDLINE | ID: mdl-17058987

RESUMEN

Man ingests food to mitigate hunger (mediated by physiological and biochemical signals), satisfy appetite (subjective sensation) and because of psychosocial reasons. Satiation biomarkers (stop feeding) are gastric distention and hormones (CCK, GLP-1) and satiety biomarkers (induce feeding) are food-induced thermogenesis, body temperature, glycaemia and also hormones (insulin, leptin and ghrelin). Oxidative metabolism/body composition, tryptophan/serotonin and proinflammatory cytokines are also implicated on hunger physiology. At the present time, ghrelin is the only known circulating orexigenic with potential on hunger/body weight regulation. It is a neuropeptide (endogenous ligand for the GH secretagogue) recently isolated from the oxyntic mucosa and synthesized mainly in the stomach. Its blood concentration depends on diet, hyperglucemia and adiposity/leptin. It is secreted 1-2 hours preprandially and its concentration decreases drastically during the postprandium. Ghrelin acts on the lateral hypothalamus and theoretically inhibits proinflammatory cytokine secretion and antagonizes leptin. Ghrelin physiologically increases food intake and stimulates adipogenesis, gastrointestinal motility and gastric acid secretion, and has other hormonal and cardiovascular functions. Ghrelin blood concentration is reduced in massive obesity, non-alcoholic steatohepatitis, polycystic ovary syndrome, acromegaly, hypogonadism, ageing, short bowel syndrome and rheumatoid arthritis; and increased in primary or secondary anorexia, starvation, chronic liver disease and celiac disease. Cerebral and peritoneal ghrelin administration (rats) and systemic administration (rats and healthy volunteers, cancer patients or patients on peritoneal dialysis) promotes food consumption and increases adiposity, of utmost importance in the treatment of patients with anorexia.


Asunto(s)
Hambre/fisiología , Hormonas Peptídicas/fisiología , Apetito/fisiología , Ghrelina , Humanos , Saciedad/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA